Literature DB >> 6121186

Relative contributions of insulin deficiency and insulin resistance in maturity-onset diabetes.

R C Turner, D R Mathews, R R Holman, J Peto.   

Abstract

The effects of raised insulin resistance and decreased beta-cell function on basal plasma glucose and insulin concentrations have been estimated by means of a mathematical model which uses the available data on control of glucose and insulin flux. The model shows that near-normal basal plasma insulin levels could be maintained by means of basal hyperglycaemia when beta-cell function is deficient. The hyperglycaemia does not become pronounced until more than 80% of beta-cell function has been lost. However, when only 5-10% of beta-cell remains, plasma insulin levels fall in spite of hyperglycaemic stimulation. Conversely, raised insulin resistance in the absence of decreased beta-cell function induces only a small rise in basal plasma glucose concentrations, which stimulates a compensatory increase in basal plasma insulin concentrations from a normal beta-cell capacity. However, if the beta-cell dysfunction is sufficient to induce a basal plasma glucose concentration of 5-6 mmol/l, a slight rise in insulin resistance causes pronounced basal hyperglycaemia.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6121186     DOI: 10.1016/s0140-6736(82)91753-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  14 in total

1.  Diabetes mellitus: a risk factor in patients with Graves' orbitopathy.

Authors:  R Kalmann; M P Mourits
Journal:  Br J Ophthalmol       Date:  1999-04       Impact factor: 4.638

2.  Hypertension and non-insulin dependent diabetes.

Authors:  J S Yudkin
Journal:  BMJ       Date:  1991-09-28

Review 3.  When to use insulin in the maturity onset diabetic.

Authors:  R B Tattersall; A R Scott
Journal:  Postgrad Med J       Date:  1987-10       Impact factor: 2.401

4.  The 'accelerator hypothesis': relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9,248 German and Austrian children with type 1 diabetes mellitus.

Authors:  I Knerr; J Wolf; T Reinehr; R Stachow; M Grabert; E Schober; W Rascher; R W Holl
Journal:  Diabetologia       Date:  2005-11-11       Impact factor: 10.122

5.  Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

Authors:  S Kumar; A J Boulton; H Beck-Nielsen; F Berthezene; M Muggeo; B Persson; G A Spinas; S Donoghue; S Lettis; P Stewart-Long
Journal:  Diabetologia       Date:  1996-06       Impact factor: 10.122

6.  Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man.

Authors:  J P Hosker; D R Matthews; A S Rudenski; M A Burnett; P Darling; E G Bown; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

7.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

8.  The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin?

Authors:  I Peacock; R B Tattersall
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-30

9.  Distinct histologic patterns of acute, prolonged, and chronic rejection in vascularized rat pancreas allografts.

Authors:  B Steiniger; J Klempnauer
Journal:  Am J Pathol       Date:  1986-08       Impact factor: 4.307

10.  Beta cell (dys)function in non-diabetic offspring of diabetic patients.

Authors:  M Stadler; G Pacini; J Petrie; A Luger; C Anderwald
Journal:  Diabetologia       Date:  2009-09-12       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.